Filing Details

Accession Number:
0001209191-17-030977
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-09 16:45:55
Reporting Period:
2017-05-09
Filing Date:
2017-05-09
Accepted Time:
2017-05-09 16:45:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1397906 Albert Cha C/O Biohaven Pharmaceuticals, Inc.
234 Church Street
New Haven CT 06510
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2017-05-09 1,506,818 $0.00 1,506,818 No 4 C Indirect See footnote
Common Shares Acquisiton 2017-05-09 470,000 $17.00 1,976,818 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Series A Preferred Shares Disposition 2017-05-09 1,506,818 $0.00 1,506,818 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. Represents shares received upon conversion of Series A Preferred Shares.
  2. The shares are held as follows: 1,323,990 shares are held by Vivo Capital Fund VIII, L.P. ("VCF") and 182,828 shares are held by Vivo Capital Surplus Fund VIII, L.P. ("VCSF"). The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
  3. The shares are held as follows: 412,973 shares are held by VCF and 57,027 shares are held by VCSF. The reporting person is one of the managing members of Vivo Capital VIII, LLC which is the general partner of both VCF and VCSF, and may be deemed to share voting and dispositive power over the shares held by VCF and VCSF. The reporting person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.
  4. Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date.